Medical Director, Urologic Oncology Program- Samuel Oschin Comprehensive Cancer Center at Cedars-Sinai Medical Center Assistant Professor, Department of Medicine, Cedars-Sinai Medical Center Clinical Associate Professor, Medicine, University of Califo
Oncology
Dr. Edwin Posadas, MD
Edwin Posadas works in the field of Oncology. He went to Johns Hopkins University School of Medicine. Johns Hopkins University School of Medicine is one of the top medical schools in the US. Johns Hopkins University School of Medicine has a rank of 3 in research and a 29 in primary care He has 2 awards "Top Doctors:LA Area" and "Fellow". Doctor Edwin Posadas, MD is a published doctor and has 39 publications published. The lastest was: 'Chaotic oscillations in cultured cells: rat prostate cancer.' He accepts all Medicare patients.
Publications
- A comparison of isolated circulating tumor Cells and tissue biopsies using whole-genome sequencing in prostate cancer.
- Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate Cancer? Results from the Shared Equal Access Regional Cancer Hospi...
- Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate Cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinic...
- miR-154* and miR-379 in the DLK1-DIO3 MicroRNA Mega-Cluster Regulate Epithelial to Mesenchymal Transition and Bone Metastasis of Prostate Cancer.
- Targeting angiogenesis in renal Cell carcinoma.
- NanoVelcro Chip for CTC enumeration in prostate Cancer patients.
- A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate Cancer.
- Detection of live circulating tumor Cells by a class of near-infrared heptamethine carbocyanine dyes in patients with localized and metastatic prostate cancer.
- Proteomic analysis for the early detection and rational treatment of Cancer--realistic hope?
- Proteomics in Cancer.
- Proteomics and ovarian Cancer: implications for diagnosis and treatment: a critical review of the recent literature.
- Approaches to inhibit invasiveness and metastasis in prostate Cancer.
- The emerging role of bisphosphonates in prostate Cancer.
- Chaotic oscillations in cultured Cells: rat prostate cancer.
- A phase II study of perifosine in androgen independent prostate Cancer.
- Management of patients with metastatic Cancer of unknown primary.
- Fyn is downstream of the HGF/MET signaling axis and affects Cellular shape and tropism in PC3 Cells.
- A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Carcinoma.
- Fyn: a novel molecular target in Cancer.
- Renal medullary-like carcinoma in an adult without sickle Cell hemoglobinopathy.
- Pazopanib: therapeutic developments.
- Kinase inhibitors in prostate Cancer.
- Phase II trial of carboplatin and paclitaxel in papillary renal Cell carcinoma.
- FYN is overexpressed in human prostate Cancer.
- Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
- A prospective analysis of imatinib-induced c-KIT modulation in ovarian Cancer: a phase II clinical study with proteomic profiling.
- A phase II study of ixabepilone (BMS-247550) in metastatic renal-Cell carcinoma.
- A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian Cancer.
- Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate Cancer.
- Phase 2 trial of linifanib (ABT-869) in patients with advanced renal Cell cancer after sunitinib failure.
- A randomized, phase II study of pazopanib in castrate-sensitive prostate Cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clin...
- Dasatinib combined with docetaxel for castration-resistant prostate Cancer: Results from a phase 1-2 study.
- Individualized decision-making for older men with prostate Cancer: balancing Cancer control with treatment consequences across the clinical spectrum.
- A phase II clinical trial of sorafenib in androgen-independent prostate Cancer.
- Phase II study of dasatinib in patients with metastatic castration-resistant prostate Cancer.
- A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate Cancer: a California Cancer Consortium study.
- A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate Cancer.
- Non-Hodgkin''s Lymphoma in Job''s syndrome: a case report and literature review.
Schools
Johns Hopkins University School of Medicine
Procedures Preformed
- Thoracentesis
Conditions Treated
- Anemia
- Basal Cell Carcinoma
- Bladder Cancer
- Coagulation Disorders (incl. Hemophilia)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Choice Plus POS II
- Blue Card PPO
- Blue Cross Blue Shield of California PPO
- Access Plus Savenet
- Basic PPO
- Great West Healthcare-Cigna PPO
- Commercial Insurance Company
- Covered California - Bronze PPO
- Health Net PPO
- Individual and Family PPO
- Medicare MCR
- Kaiser PHCS Network PPO
- MultiPlan PPO
- PHCS Network PPO
- Sagamore Plus
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- Top Doctors:LA Area
- Fellow
Education
-
National Institutes of Health Clinical Center -
University of Michigan Hospitals and Health Centers -
Johns Hopkins University School of Medicine
Hospital
-
Cedars-Sinai Medical Center
Drug Facts
| NPI NUMBER | 1720140270 | |
| NPPES Provider LastName | POSADAS | |
| NPPES Provider FirstName | EDWIN | |
| NPPES Provider ZIPCode | 605276686 | |
| NPPES Provider State | IL | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 361.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 12.0 | |
| Percent Opioid Claims | 3.32 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1720140270 |
| Last Name Of The Provider | POSADAS |
| First Name Of The Provider | EDWIN |
| View All |
Similar Doctors
|
Dr. Renee H. Jacobs, MD |
|
|
Dr. Dorothy Sipkins, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas F. Gajewski, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Todd L. Zimmerman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark J. Ratain, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Everett E. Vokes, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Olatoyosi Odenike, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Andrea R. Dean, MD
This Doctor is OpenDoctor Recommended.
|